About Verve Therapeutics
Verve Therapeutics is a company based in Cambridge (United States) founded in 2018 by J Keith Joung, Issi Rozen, and Burt Adelman was acquired by Lilly in June 2025. It operates as a HealthTech. Verve Therapeutics has raised $215.5 million across 3 funding rounds from investors including Lilly, Citadel and Janus Henderson Investors. The company has 255 employees as of December 31, 2023. Verve Therapeutics offers products and services including VERVE-102 and VERVE-201. Verve Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 255 as on 31 Dec, 2023
- Founders J Keith Joung, Issi Rozen, Burt Adelman
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Verve Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$198.71 M (USD)1as on Dec 31, 2024
-
EBITDA
-$228.66 M (USD)-2as on Dec 31, 2024
-
Total Equity Funding
$215.5 M (USD)
in 3 rounds
-
Latest Funding Round
$94 M (USD), Series B
Jan 19, 2021
-
Investors
Lilly
& 14 more
-
Employee Count
255
as on Dec 31, 2023
-
Acquired by
Lilly
(Jun 17, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Verve Therapeutics
Verve Therapeutics offers a comprehensive portfolio of products and services, including VERVE-102 and VERVE-201.
Gene editing therapy targeting PCSK9 for LDL-C reduction.
Gene editing solution addressing cardiovascular disease risk factors.
People of Verve Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Verve Therapeutics
Verve Therapeutics has successfully raised a total of $215.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $94 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Verve Therapeutics
Verve Therapeutics has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Citadel and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked |
Investor details for Verve Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Verve Therapeutics
Investment portfolio details for Verve Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Verve Therapeutics
Detailed financials for Verve Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Verve Therapeutics Comparisons
Peer comparison for Verve Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Verve Therapeutics
Verve Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
Detailed competitors of Verve Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Verve Therapeutics
Complete news archive for Verve Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Verve Therapeutics
Verve Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Verve Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Verve Therapeutics is a funded company, having raised a total of $215.5M across 3 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Verve Therapeutics is 255.
Verve Therapeutics is dedicated to combating cardiovascular disease (CVD), the leading cause of death worldwide, through innovative single-course gene editing medicines. Solutions are developed to inactivate specific genes in the liver that contribute to CVD risk. The pipeline includes programs like VERVE-102 and VERVE-201, targeting conditions such as heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. Advances in human genetics and gene editing technologies are leveraged to transform the treatment paradigm for hundreds of millions affected by atherosclerotic cardiovascular disease (ASCVD).
Verve Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Verve Therapeutics offers VERVE-102 and VERVE-201.
Verve Therapeutics has 15 investors. Key investors include Lilly, Citadel, Janus Henderson Investors, RA Capital, and Arch Venture Partners.